Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT04521153 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

294

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Immunotherapy
Molecular Targeted Therapy

Interventions

DRUG: Camrelizumab
DRUG: Apatinib Mesylate
PROCEDURE: Radical surgery

Sponsor

Shanghai Zhongshan Hospital